Delving into the Latest Updates on CGT-1881 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

CXCR4

Mechanism

CXCR4 antagonists(C-X-C motif chemokine receptor 4 antagonists)

Therapeutic Areas

NeoplasmsImmune System DiseasesCardiovascular Diseases+ [2]

Active Indication

Multiple MyelomaStem cell mobilisation

Inactive Indication-

Originator Organization

CGeneTech (Suzhou, China) Co. Ltd.

Active Organization

CGeneTech (Suzhou, China) Co. Ltd.

Inactive Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Login to view timeline

I期试验：主要评价健康受试者单次口服CGT-1881的安全性和耐受性以及高脂饮食对健康受试者单次口服CGT-1881的药代动力学和药效学特征的影响。 IIa期试验：主要评价NHL或MM患者单次口服CGT-1881的安全性、耐受性以及多次口服CGT-1881的安全性、耐受性和初步有效性。

[Translation]

Phase I trial: mainly evaluates the safety and tolerability of a single oral dose of CGT-1881 in healthy subjects and the effects of a high-fat diet on the pharmacokinetic and pharmacodynamic characteristics of a single oral dose of CGT-1881 in healthy subjects. Phase IIa trial: mainly evaluates the safety, tolerability of a single oral dose of CGT-1881 in patients with NHL or MM, as well as the safety, tolerability and preliminary efficacy of multiple oral doses of CGT-1881.

Start Date15 May 2023

Sponsor / Collaborator

CGeneTech (Suzhou, China) Co. Ltd.

100 Clinical Results associated with CGT-1881

Login to view more data

100 Translational Medicine associated with CGT-1881

Login to view more data

100 Patents (Medical) associated with CGT-1881

Login to view more data

100 Deals associated with CGT-1881

Login to view more data